Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

Summary

The aim of this study is to evaluate the clinical efficacy of sirolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.

Timeline

Start

2024-12-23

Primary completion

2027-12-01

Completion

2028-12-01

Drugs

Indications